Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 2/20 | 0.56 |
| ▸ | MAP3K5 | Q99683 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NNMT | P40261 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18323129 | 0.81 | F10 (0.45) | MTORMAP3K5RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL15907179 | 0.78 | RAB9A (0.52) | MTORRAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL15907219 | 0.78 | MTOR (0.57) | MTORRAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL624251 | 0.76 | L3MBTL1 (0.53) | MTORRAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL25223673 | 0.75 | PTGS1 (0.62) | MTORRAB9ATSHRMEN1KMT2A | |
| SCHEMBL31627738 | 0.73 | MTOR (0.44) | MTORRAB9ASMN1; SMN2TP53NPC1 | |
| SCHEMBL15907218 | 0.70 | MTOR (0.43) | MTORRAB9ASMN1; SMN2TP53NPC1 | |
| SCHEMBL15907222 | 0.70 | MTOR (0.43) | MTORMAP3K5RAB9ASMN1; SMN2TP53 | |
| SCHEMBL11308749 | 0.69 | HCAR3 (0.77) | RAB9ASMN1; SMN2KDM4ENNMTNPC1 | |
| SCHEMBL15308200 | 0.69 | KMT2A (0.57) | RAB9AKDM4ENPC1POLBCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | MTOR 348/4885MAP3K5 9/4885RAB9A 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.